PT  - JOURNAL ARTICLE
AU  - Darlan S. Candido
AU  - Ingra M. Claro
AU  - Jaqueline G. de Jesus
AU  - William M. Souza
AU  - Filipe R. R. Moreira
AU  - Simon Dellicour
AU  - Thomas A. Mellan
AU  - Louis du Plessis
AU  - Rafael H. M. Pereira
AU  - Flavia C. S. Sales
AU  - Erika R. Manuli
AU  - Julien Thézé
AU  - Luiz Almeida
AU  - Mariane T. Menezes
AU  - Carolina M. Voloch
AU  - Marcilio J. Fumagalli
AU  - Thais M. Coletti
AU  - Camila A. M. Silva
AU  - Mariana S. Ramundo
AU  - Mariene R. Amorim
AU  - Henrique Hoeltgebaum
AU  - Swapnil Mishra
AU  - Mandev S. Gill
AU  - Luiz M. Carvalho
AU  - Lewis F. Buss
AU  - Carlos A. Prete, Jr
AU  - Jordan Ashworth
AU  - Helder Nakaya
AU  - Pedro S. Peixoto
AU  - Oliver J. Brady
AU  - Samuel M. Nicholls
AU  - Amilcar Tanuri
AU  - Átila D. Rossi
AU  - Carlos K.V. Braga
AU  - Alexandra L. Gerber
AU  - Ana Paula Guimarães
AU  - Nelson Gaburo, Jr
AU  - Cecila S. Alencar
AU  - Alessandro C.S. Ferreira
AU  - Cristiano X. Lima
AU  - José Eduardo Levi
AU  - Celso Granato
AU  - Giula M. Ferreira
AU  - Ronaldo S. Francisco, Jr
AU  - Fabiana Granja
AU  - Marcia T. Garcia
AU  - Maria Luiza Moretti
AU  - Mauricio W. Perroud, Jr
AU  - Terezinha M. P. P. Castineiras
AU  - Carolina S. Lazari
AU  - Sarah C. Hill
AU  - Andreza A. de Souza Santos
AU  - Camila L. Simeoni
AU  - Julia Forato
AU  - Andrei C. Sposito
AU  - Angelica Z. Schreiber
AU  - Magnun N. N. Santos
AU  - Camila Zolini de Sá
AU  - Renan P. Souza
AU  - Luciana C. Resende-Moreira
AU  - Mauro M. Teixeira
AU  - Josy Hubner
AU  - Patricia A. F. Leme
AU  - Rennan G Moreira
AU  - Maurício Lacerda Nogueira
AU  - CADDE-Genomic-Network
AU  - Neil M Ferguson
AU  - Silvia F. Costa
AU  - José Luiz Proenca-Modena
AU  - Ana Tereza R. Vasconcelos
AU  - Samir Bhatt
AU  - Philippe Lemey
AU  - Chieh-Hsi Wu
AU  - Andrew Rambaut
AU  - Nick J. Loman
AU  - Renato S. Aguiar
AU  - Oliver G. Pybus
AU  - Ester C. Sabino
AU  - Nuno Rodrigues Faria
TI  - Evolution and epidemic spread of SARS-CoV-2 in Brazil
AID  - 10.1101/2020.06.11.20128249
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.11.20128249
4099  - http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128249.short
4100  - http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128249.full
AB  - Brazil currently has one of the fastest growing SARS-CoV-2 epidemics in the world. Due to limited available data, assessments of the impact of non-pharmaceutical interventions (NPIs) on virus transmission and epidemic spread remain challenging. We investigate the impact of NPIs in Brazil using epidemiological, mobility and genomic data. Mobility-driven transmission models for São Paulo and Rio de Janeiro cities show that the reproduction number (Rt) reached below 1 following NPIs but slowly increased to values between 1 to 1.3 (1.0–1.6). Genome sequencing of 427 new genomes and analysis of a geographically representative genomic dataset from 21 of the 27 Brazilian states identified >100 international introductions of SARS-CoV-2 in Brazil. We estimate that three clades introduced from Europe emerged between 22 and 27 February 2020, and were already well-established before the implementation of NPIs and travel bans. During this first phase of the epidemic establishment of SARS-CoV-2 in Brazil, we find that the virus spread mostly locally and within-state borders. Despite sharp decreases in national air travel during this period, we detected a 25% increase in the average distance travelled by air passengers during this time period. This coincided with the spread of SARS-CoV-2 from large urban centers to the rest of the country. In conclusion, our results shed light on the role of large and highly connected populated centres in the rapid ignition and establishment of SARS-CoV-2, and provide evidence that current interventions remain insufficient to keep virus transmission under control in Brazil.One Sentence Summary Joint analysis of genomic, mobility and epidemiological novel data provide unique insight into the spread and transmission of the rapidly evolving epidemic of SARS-CoV-2 in Brazil.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Sao Paulo Research Foundation (FAPESP) and Medical Research Council CADDE partnership award (MR/S0195/1) (http://caddecentre.org/), FAPESP (2018/14389-0) and the Oxford Martin School. NRF is supported by a Sir Henry Dale Fellowship (204311/Z/16/Z). WMS is supported by FAPESP, Brazil (No. 2017/13981-0). SD is supported by the Fonds National de la Recherche Scientifique (FNRS, Belgium). NL, AR and PL are supported by the Wellcome Trust ARTIC network (Collaborators Award 206298/Z/17/Z). PL and AR are supported by the European Research Council (grant agreement no. 725422 - ReservoirDOCS). OJB was funded by a Sir Henry Wellcome Fellowship funded by the Wellcome Trust (206471/Z/17/Z). VHN and CAP were supported by FAPESP (2018/12579-7). JLPM, MRA and CLS are supported by FAPESP (2020/04558-0). MLN is supported by FAPESP (2020/04836-0). LdP is supported by Oxford Martin School; ATRV is supported by CNPq (303170/2017-4) and FAPERJ (26/202.903/20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual nasopharyngeal, tracheal and bronchial aspirate samples testing positive for SARS-CoV-2 by RT-qPCR were obtained from public health and private medical diagnostics laboratories (Table S1). All samples were de-identified before receipt by the researchers. Ethics approval for this study was approved by the national ethical review board (Comissao Nacional de Etica em Pesquisa), protocol number CAAE 30127020.0.0000.0068All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, code, and materials used in the analysis are available on our Dryad and GitHub repository (upon acceptance).